A breathtaking and bloodcurdling story of coagulation and inflammation in acute lung injury

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 12, 2009, Pages 2050-2052

  Schultz, M J ^a,b   Dixon, B ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b HERMES Critical Care Group   (Netherlands)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LUNG INJURY; BLOOD; BLOOD CLOTTING; HUMAN; INFLAMMATION; NOTE; PATHOLOGY; SYSTEMS BIOLOGY;

ACUTE LUNG INJURY; BLOOD COAGULATION; HUMANS; INFLAMMATION; SYSTEMS BIOLOGY;

EID: 77449142823     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03639.x     Document Type: Note

References (29)

1. Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas 2004; 47: 305-14.
2. Levi M, Van Der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698-704.
3. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, Seeger W. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 454-62.
4. Schultz MJ, Millo J, Levi M, Hack CE, Weverling GJ, Garrard CS, Van Der Poll T. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004; 59: 130-5.
5. Dehoux MS, Boutten A, Ostinelli J, Seta N, Dombret MC, Crestani B, Deschenes M, Trouillet JL, Aubier M. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994; 150: 710-6.
6. Pugin J, Verghese G, Widmer MC, Matthay MA. The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. Crit Care Med 1999; 27: 304-12.
7. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-78.
8. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290: 238-47.
9. Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, Aguirre D, Munoz A. Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med 2009; 37: 1185-96.
10. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
11. Abraham E. Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol 2000; 22: 401-4.
12. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia--a review. Crit Care Med 2006; 34: 871-7.
13. Laterre P-F, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet J-P, Maki DG, Bates B, Yan SCB, Dhainaut J-F. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005; 33: 952-61.
14. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, Tidswell M, Siegel MD, Soto G, Peterson MW, Chesnutt MS, Phillips C, Weinacker A, Thompson BT, Eisner MD, Matthay MA. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008; 178: 618-23.
15. Choi G, Schultz MJ, Levi M, Van Der Poll T. The relationship between inflammation and the coagulation system. Swiss Med Wkly 2006; 136: 139-44.
16. Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O'Brien J, Gruber M, Zarini S, Murphy RC, Kuhn K, Richter D, Kast KR, Abraham E. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004; 104: 3878-85.
17. Van Der Poll T, Levi M, Nick JA, Abraham E. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005; 171: 1125-8.
18. Takagi T, Taguchi O, Aoki S, Toda M, Yamaguchi A, Fujimoto H, Boveda-Ruiz D, Gil-Bernabe P, Ramirez AY, Yano Y, D'Alessandro-Gabazza CN, Fujiwara A, Takei Y, Morser J, Gabazza EC. Direct effects of protein S in ameliorating acute lung injury. J Thromb Haemost 2009; 7: 2053-63.
19. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997; 272: L197-202.
20. Okajima K. Antithrombin prevents endotoxin-induced pulmonary vascular injury by inhibiting leukocyte activation. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 2): S25-37.
21. Giebler R, Schmidt U, Koch S, Peters J, Scherer R. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin. Crit Care Med 1999; 27: 597-604.
22. Yasui H, Gabazza EC, Tamaki S, Kobayashi T, Hataji O, Yuda H, Shimizu S, Suzuki K, Adachi Y, Taguchi O. Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am J Respir Crit Care Med 2001; 163: 1660-8.
23. Choi G, Hofstra JJ, Roelofs JJ, Florquin S, Bresser P, Levi M, Van Der Poll T, Schultz MJ. Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med 2007; 35: 1362-8.
24. Choi G, Hofstra JJ, Roelofs JJ, Rijneveld AW, Bresser P, Van Der Zee JS, Florquin S, Van Der Poll T, Levi M, Schultz MJ. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 2008; 36: 204-10.
25. Hofstra JJ, Cornet AD, Choi G, Van Der Poll T, Levi M, Schultz MJ. Locally Applied Antithrombin Inhibits Pulmonary Coagulopathy during Streptococcus pneumoniae Pneumonia in rats. Crit Care 2009; 13: R145.
26. Hofstra JJ, Juffermans NP, Schultz MJ, Zweers MM. Pulmonary coagulopathy as a new target in lung injury--a review of available pre-clinical models. Curr Med Chem 2008; 15: 588-95.
27. Hofstra JJ, Dixon B, Cornet AD, Choi G, Van Der Poll T, Levi M, Schultz MJ. Nebulized Anticoagulants Limit Pulmonary Coagulopathy in Clinical and Experimental Acute Lung injury. J Aerosol Med Pulm Drug Deliv 2009; in press.
28. Lahteenmaki K, Kuusela P, Korhonen TK. Bacterial plasminogen activators and receptors. FEMS Microbiol Rev 2001; 25: 531-52.
29. Dixon B, Santamaria JD, Campbell DJ. A phase 1 trial of nebulised heparin in acute lung injury. Crit Care 2008; 12: R64.